Stockscreener 앱 받기
1.86
0.53%
-0.01
시간 외 거래:
1.90
0.04
+2.15%
전일 마감가:
$1.87
열려 있는:
$1.895
하루 거래량:
42,670
Relative Volume:
0.34
시가총액:
$93.75M
수익:
-
순이익/손실:
-
주가수익비율:
-
EPS:
-
순현금흐름:
-
1주 성능:
-1.59%
1개월 성능:
+10.06%
6개월 성능:
+0.00%
1년 성능:
+0.00%
1일 변동 폭
$1.86
$1.99
1주일 범위
$1.825
$1.99
52주 변동 폭
$1.39
$2.20
Whitehawk Therapeutics Inc Stock (WHWK) Company Profile
명칭
Whitehawk Therapeutics Inc
전화
551-321-2234
주소
2 HEADQUARTERS PLAZA, MORRISTOWN
WHWK을(를) 다른 주식과 비교
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
WHWK
Whitehawk Therapeutics Inc
|
1.86 | 93.75M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.16 | 115.95B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
534.91 | 56.52B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
322.06 | 39.44B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
542.47 | 35.14B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
245.16 | 28.51B | 3.81B | -644.79M | -669.77M | -6.24 |
Whitehawk Therapeutics Inc Stock (WHWK) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-08-27 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2024-08-21 | 다운그레이드 | Jefferies | Buy → Hold |
| 2024-08-21 | 다운그레이드 | TD Cowen | Buy → Hold |
| 2023-12-15 | 다운그레이드 | H.C. Wainwright | Buy → Neutral |
| 2022-01-11 | 개시 | Jefferies | Buy |
| 2021-10-01 | 개시 | Cowen | Outperform |
| 2021-09-14 | 개시 | Ladenburg Thalmann | Buy |
| 2021-09-08 | 개시 | Piper Sandler | Overweight |
모두보기
Whitehawk Therapeutics Inc 주식(WHWK)의 최신 뉴스
Whitehawk Therapeutics reports annual meeting results By Investing.com - Investing.com South Africa
Whitehawk Therapeutics reports annual meeting results - Investing.com
Whitehawk Therapeutics Elects Directors at Annual Meeting - TipRanks
Implied Volatility Surging for Whitehawk Therapeutics Stock Options - sharewise
Aadi Bioscience to Present at Upcoming Investor Conferences - marketscreener.com
Whitehawk Therapeutics to Present at the Jefferies 2025 Global Healthcare Conference - PR Newswire
Whitehawk Therapeutics to Participate in the TD Cowen 6th Annual Oncology Innovation Summit - PR Newswire
Whitehawk Therapeutics Reports Strong Q1 2025 Results - TipRanks
Whitehawk Therapeutics May 2025 slides: Pivoting to ADC development with three candidates - Investing.com Canada
Whitehawk Therapeutics, Inc. SEC 10-Q Report - TradingView
Whitehawk Reports First Quarter 2025 Financial Results and Recent Highlights - Stock Titan
WHWK Stock Sees Surge of Approximately 10.60% in Last Five Days - knoxdaily.com
Should You Expect A Quick Recovery From Whitehawk Therapeutics Inc (NASDAQ: WHWK) After -128.14% Decline From High? – Marketing Sentinel - Marketing Sentinel
Whitehawk Therapeutics Inc: Navigating Market Fluctuations with a 73.92M Market Cap - investchronicle.com
A review of WHWK’s current quarter earnings predictions - uspostnews.com
Whitehawk Therapeutics - The Pharma Letter
Aadi Bioscience Reports Interim Results from PRECISION1 Trial of nab-Sirolimus Demonstrating Anti-Tumor Activity in Solid Tumors with TSC1 or TSC2 Inactivating Alterations - MarketScreener
Aadi Bioscience to Participate at Upcoming Investor Conferences - MarketScreener
Aadi Bioscience to Participate in Upcoming Investor Events - MarketScreener
Aadi Bioscience Announces Poster Presentations at 2023 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics - MarketScreener
Aadi Bioscience Announces Poster Presentations on Nab-Sirolimus at the International Gynecologic Cancer Society (IGCS) 2023 Annual Global Meeting - MarketScreener
Aadi Bioscience to Present at the TD Cowen 44th Annual Healthcare Conference - MarketScreener
Aadi Bioscience, Inc. Announces First Patient Dosed in its PRECISION 1 Phase 2 Registrational Trial of nab-Sirolimus in Patients with Solid Tumors Harboring Pathogenic Inactivating Alterations in TSC1 and TSC2 Genes - MarketScreener
Earnings Flash (AADI) AADI BIOSCIENCE Posts Q4 Revenue $5.2M - MarketScreener
Whitehawk Therapeutics, Inc. SEC 10-K Report - TradingView
Kaken Pharmaceutical Co., Ltd. entered into a stock purchase agreement to acquire Aadi Subsidiary, Inc. from Aadi Bioscience, Inc. for $100 million. - marketscreener.com
Whitehawk Therapeutics Closes Sale of Aadi Subsidiary to Kaken Pharmaceuticals - citybiz
Whitehawk Therapeutics sells subsidiary for $102.4 million By Investing.com - Investing.com South Africa
Whitehawk Therapeutics sells subsidiary for $102.4 million - Investing.com India
Whitehawk sells Aadi Subsidiary to Kaken for $100 million - Investing.com
Whitehawk sells Aadi Subsidiary to Kaken for $100 million By Investing.com - Investing.com India
Whitehawk Therapeutics Completes Strategic Transformation With Successful Closing Of Sale Of Aadi Subsidiary To Kaken Pharmaceuticals - Marketscreener.com
Whitehawk Therapeutics Completes Strategic Transformation with Successful Closing of Sale of Aadi Subsidiary to Kaken Pharmaceuticals - The Victoria Advocate
Aadi Bioscience Announces $72.5 Million Private Placement Equity Financing - MarketScreener
Aadi Bioscience Announces Participation in Upcoming September Investor Conferences - MarketScreener
Aadi Bioscience Announces Leadership Transition - MarketScreener
Aadi Bioscience Announces Improved Anti-Tumor Activity of KRAS Inhibitors in Combination with Nab-sirolimus at the 34th EORTC-NCI-AACR Symposium - MarketScreener
Aadi Bioscience, Inc. (NASDAQ:AADI) Q4 2024 Earnings Call Transcript - Insider Monkey
Aadi Bioscience’s Earnings Call: Strategic Shifts and Promising Pipeline - TipRanks
Aadi Bioscience, Inc. Appoints Baiteng Zhao to its Board of Directors - MarketScreener
Aadi Bioscience Announces Financial Results for the First Quarter 2024 and Provides Corporate Update - Marketscreener.com
Aadi Bioscience Announces Financial Results for the Third Quarter 2024 and Provides Corporate Update - MarketScreener
Aadi Bioscience Announces Financial Results for the Second Quarter 2024 and Provides Corporate Update - Marketscreener.com
Aadi Bioscience, Inc. Announces CEO Changes - MarketScreener
Aadi Bioscience Presents New Subgroup Analysis of Patients with Advanced Malignant PEComa of Gynecologic Origin Treated with nab-Sirolimus at Society of Gynecologic Oncology (SGO) - Marketscreener.com
Aadi Bioscience to Participate in the Jefferies Healthcare Conference - MarketScreener
Aadi Bioscience Appoints David Dornan, PhD, as Chief Scientific Officer - MarketScreener
Aadi Bioscience Announces Approval of All Proposals at Special Meeting of Stockholders - Marketscreener.com
Aadi Bioscience Inc (AADI) Q4 2024 Earnings Call Highlights: Strategic Transition and Financial ... By GuruFocus - Investing.com Canada
Whitehawk Therapeutics: Strategic Shift and Financial Outlook - TipRanks
Aadi rebrands as Whitehawk Therapeutics in new ADC focus - The Pharma Letter
Whitehawk Therapeutics Inc (WHWK) 재무 분석
Whitehawk Therapeutics Inc (WHWK)에 대한 금융 데이터가 없습니다. 더 많은 정보를 위해 다른 주식을 확인해보세요.
매출
순이익
현금흐름
주당 순 이익
Whitehawk Therapeutics Inc 주식 (WHWK) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| Giacobello Scott M. | CHIEF FINANCIAL OFFICER |
Mar 03 '25 |
Sale |
2.35 |
2,806 |
6,594 |
23,944 |
| Lennon David James | CHIEF EXECUTIVE OFFICER |
Mar 03 '25 |
Sale |
2.35 |
5,690 |
13,372 |
33,429 |
0.39%
0.42%
자본화:
|
볼륨(24시간):